Compagnie Lombard Odier SCmA raised its position in shares of Abbott Laboratories (NYSE:ABT) by 0.5% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 133,157 shares of the healthcare product maker’s stock after purchasing an additional 629 shares during the quarter. Compagnie Lombard Odier SCmA’s holdings in Abbott Laboratories were worth $6,472,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Heritage Trust Co lifted its position in shares of Abbott Laboratories by 10.1% during the 2nd quarter. Heritage Trust Co now owns 2,175 shares of the healthcare product maker’s stock valued at $106,000 after acquiring an additional 200 shares during the last quarter. Winfield Associates Inc. lifted its position in shares of Abbott Laboratories by 3.9% during the 2nd quarter. Winfield Associates Inc. now owns 2,382 shares of the healthcare product maker’s stock valued at $116,000 after acquiring an additional 89 shares during the last quarter. Thompson Davis & CO. Inc. lifted its position in shares of Abbott Laboratories by 17.7% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 2,463 shares of the healthcare product maker’s stock valued at $120,000 after acquiring an additional 370 shares during the last quarter. JFS Wealth Advisors LLC lifted its position in shares of Abbott Laboratories by 349.0% during the 2nd quarter. JFS Wealth Advisors LLC now owns 2,694 shares of the healthcare product maker’s stock valued at $131,000 after acquiring an additional 2,094 shares during the last quarter. Finally, Motco lifted its position in shares of Abbott Laboratories by 213.7% during the 2nd quarter. Motco now owns 2,880 shares of the healthcare product maker’s stock valued at $140,000 after acquiring an additional 1,962 shares during the last quarter. 71.32% of the stock is owned by hedge funds and other institutional investors.
Shares of Abbott Laboratories (NYSE ABT) opened at $54.64 on Monday. The stock has a market capitalization of $95,106.44, a price-to-earnings ratio of 22.67, a PEG ratio of 2.05 and a beta of 1.06. Abbott Laboratories has a 1-year low of $37.90 and a 1-year high of $56.69. The company has a quick ratio of 2.26, a current ratio of 2.69 and a debt-to-equity ratio of 0.72.
Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.01. Abbott Laboratories had a return on equity of 13.98% and a net margin of 8.37%. The business had revenue of $6.83 billion during the quarter, compared to analyst estimates of $6.72 billion. During the same period last year, the company earned $0.59 earnings per share. Abbott Laboratories’s quarterly revenue was up 28.8% compared to the same quarter last year. sell-side analysts expect that Abbott Laboratories will post 2.49 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, November 15th. Investors of record on Friday, October 13th were issued a dividend of $0.265 per share. The ex-dividend date of this dividend was Thursday, October 12th. This represents a $1.06 annualized dividend and a dividend yield of 1.94%. Abbott Laboratories’s dividend payout ratio is 83.47%.
In related news, insider Brian J. Blaser sold 23,866 shares of the stock in a transaction on Friday, November 17th. The stock was sold at an average price of $55.55, for a total transaction of $1,325,756.30. Following the completion of the sale, the insider now directly owns 146,387 shares in the company, valued at $8,131,797.85. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Alejandro D. Wellisch sold 2,153 shares of the stock in a transaction on Wednesday, November 22nd. The stock was sold at an average price of $55.86, for a total value of $120,266.58. Following the sale, the insider now owns 10,256 shares of the company’s stock, valued at $572,900.16. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 588,013 shares of company stock valued at $32,023,946. 0.76% of the stock is owned by corporate insiders.
A number of brokerages have recently commented on ABT. ValuEngine downgraded Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Zacks Investment Research upgraded Abbott Laboratories from a “hold” rating to a “buy” rating and set a $61.00 price objective for the company in a research report on Tuesday, October 31st. Barclays reiterated an “overweight” rating on shares of Abbott Laboratories in a research report on Thursday, October 19th. Citigroup reiterated a “neutral” rating on shares of Abbott Laboratories in a research report on Thursday, October 19th. Finally, BMO Capital Markets restated a “market perform” rating on shares of Abbott Laboratories in a report on Thursday, October 19th. Eight analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $56.81.
ILLEGAL ACTIVITY WARNING: This story was first posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://transcriptdaily.com/2017/12/11/compagnie-lombard-odier-scma-raises-holdings-in-abbott-laboratories-abt.html.
Abbott Laboratories Company Profile
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.